News

Small caps round-up: Nanette, Petrel Resources, Shieldtech

20 February 2008 12:27:00

Nanette Real Estate edged ahead Wednesday after the firm announced the consolidation of its Polish operations with regional partner Lehman Brothers into one vehicle, Robyg SA.

Once the process is completed Nanette said it will hold a 48.19% stake in Robyg.

In addition, the company has secured €60m of debt finance for two real estate projects in Poland.

"Given the current credit crunch, we are particularly pleased that we were able to follow our stated strategy of obtaining capital to both finance the construction and refinance the land acquisitions," said the group.

Shares in Petrel Resources rallied on news that the Iraqi government has approved the extension of its technical cooperation agreement with the oil explorer for another year.

The group expects to embark on a new oil and gas field study as part of this programme.

"We remain entirely committed to our Southern Iraq development strategy and to working with the Iraqi Oil Ministry to help monetise the potentially vast resources available to risk aware investors," said managing director David Horgan.

There were also gains for AIM listed Shieldtech after the security products group said it has won a deal to supply an innovative modular body armour system to a major overseas defence client.

The contract has an initial value of £1.8m for goods for immediate delivery with potential further sales, including upgrades, totalling £3.2m over three years.

Book publisher Quarto said it was delighted to report improved results despite the weak economy and weak dollar.

The group's principal trading currency is the US dollar but it reports results in sterling but despite that it saw pre-tax profits rise 45% to £6.7m on revenues that rose 7% to £93.6m. Total dividend was raised 6% to 7.15p each.

"The publishing segment, by its nature, sells from inventory and does not have such forward visibility, but, even allowing for the lingering problems in the US housing and associated markets, we expect a solid performance for the group in 2008," said the group.
Gene therapy outfit Oxford BioMedica is at a fresh three-month high after the independent Data Safety Monitoring Board (DSMB) recommended that the phase III TRIST study of TroVax in renal cancer continue without modification.

The continuation of the trial following the interim analysis triggers a milestone payment from Sanofi-Aventis to Oxford BioMedica of €10m.

Media Corp has now completed the re-organisation and restructuring of the group that began after the US internet gambling ban at the end of 2006.

Now divided into Internet Publishing and Advertising sales divisions, the firm has approved a business plan to invest up to £1m of its existing cash resources on expansion during 2008.

Energy and water conservation IT services provider Qonnectis also added ground on news it has signed a memorandum of understanding to enter into a distribution agreement for its new Leakfrog product with Halma Water Management.

The definitive distribution deal will enable Qonnectis and HWM to jointly market the Leakfrog domestic leakage monitor throughout the UK and internationally.

All data suppied by Digital Look (15 minute delay)




Risk Warning

There is an extra risk of losing money when shares are bought in some smaller companies including 'Penny Shares'. There is a big difference between the buying price and the selling price of these shares. If they have to be sold immediately, you may get back much less than you paid for them or you may have difficulty in selling them. Past performance is not a reliable indicator of future results. The price may change quickly and it may go down as well as up. You could lose every penny put into a particular share.

The information contained above has been compiled from documented sources which are believed to be reliable but, due to their very nature, are subject to a degree of historical inaccuracy and have not been independently verified and cannot be guaranteed. The pages on this website are provided for information only. City Equities Limited will not accept responsibility for loss incurred by any person or body acting, or refraining from acting, as a result of information and/or opinions given anywhere on this website. Issued by City Equities Limited, Aldermary House, 10-15 Queen Street, London, EC4N 1TY. Registered in England. Registered No. 2742847. Registered Address: Amwell House, 19 Amwell Street, Hoddeson, Herts. EN11 8TS. City Equities Limited is Authorised and regulated by the Financial Services Authority. Registration No. 155051.